Arthrex Receives FDA Clearance for TightRope® Implant as First, Only Device Cleared for Pediatric ACL Surgery
NAPLES, Fla., Jan. 10, 2023 /PRNewswire/ -- Arthrex, a global leader in minimally invasive surgical technology, announced today its ACL TightRope implant has received clearance from the U.S. Food and Drug Administration (FDA) for pediatric indications. The TightRope implant is used in the surgical treatment of orthopedic injuries and is the first and only fixation device for anterior cruciate ligament (ACL) injuries cleared for pediatric use.
- The TightRope implant is used in the surgical treatment of orthopedic injuries and is the first and only fixation device for anterior cruciate ligament (ACL) injuries cleared for pediatric use.
- Cordasco and Green helped Arthrex develop pediatric and young adolescent-specific instrumentation guides to address a growing population of young athletes facing ACL injuries.
- The Arthrex all-epiphyseal technique was developed for skeletally immature patients and involves avoiding the pediatric growth plates to repair or reconstruct the ACL.
- The Arthrex ACL TightRope portfolio of fixation devices includes the ACL TightRope II implant, the TightRope attachable button system (ABS) and implant, the FiberTag® TightRope implant and the ACL Repair TightRope implant with FiberRing™ sutures.